Brief: Compugen To Receive Milestone Payment Triggered By Dosing Of First Patient In The Second Phase 3 Trial Evaluating Rilvegostomig
30/05/2024 12:22
May 30 (Reuters) - Daiichi Sankyo Co Ltd 4568.T :
* COMPUGEN TO RECEIVE MILESTONE PAYMENT TRIGGERED BY DOSING
OF
FIRST PATIENT IN THE SECOND PHASE 3 TRIAL EVALUATING
RILVEGOSTOMIG
* COMPUGEN LTD -COMPUGEN TO RECEIVE $5 MILLION MILESTONE
PAYMENT
FROM ASTRAZENECA
Source text for Eikon: ID:nPn3CnXbSa
Further company coverage: 4568.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Compugen
See all newsIsrael's Compugen Q2 revenue more than doubles, net loss narrows
Brief: Compugen Announces The Appointment Of Michele Holcomb, Ph.D., To Its Board Of Directors
Brief: Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million
Brief: Compugen Announces First Patient Dosed In Com701 Global Platform Trial In Platinum Sensitive Ovarian Cancer
Brief: Compugen Announces Leadership Transitions Effective September 2025